53,122 Repligen Corporation $RGEN Shares Acquired by Voya Investment Management LLC

Voya Investment Management LLC lifted its position in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 9.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 602,325 shares of the biotechnology company’s stock after acquiring an additional 53,122 shares during the quarter. Voya Investment Management LLC owned 0.94% of Repligen worth $115,785,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. North Dakota State Investment Board boosted its stake in shares of Repligen by 4.1% in the third quarter. North Dakota State Investment Board now owns 1,630 shares of the biotechnology company’s stock valued at $313,000 after buying an additional 64 shares in the last quarter. Bessemer Group Inc. grew its holdings in Repligen by 38.0% during the third quarter. Bessemer Group Inc. now owns 334 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 92 shares during the period. Farther Finance Advisors LLC grew its holdings in Repligen by 35.5% during the third quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 98 shares during the period. Eurizon Capital SGR S.p.A. raised its position in Repligen by 21.2% in the third quarter. Eurizon Capital SGR S.p.A. now owns 583 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 102 shares in the last quarter. Finally, ABS Investment Management LLC purchased a new position in Repligen in the second quarter worth $191,016,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Up 0.4%

RGEN opened at $173.30 on Thursday. The business’s fifty day moving average is $177.08 and its two-hundred day moving average is $145.83. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.43 and a current ratio of 9.88. The company has a market cap of $11.08 billion, a price-to-earnings ratio of -830.48, a PEG ratio of 2.78 and a beta of 1.11. Repligen Corporation has a one year low of $100.99 and a one year high of $198.87.

Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The business had revenue of $209.31 million during the quarter, compared to analysts’ expectations of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.46 earnings per share. Analysts anticipate that Repligen Corporation will post 2.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of recent analyst reports. Royal Bank Of Canada raised their target price on Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. JPMorgan Chase & Co. upped their price target on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Barclays boosted their price objective on shares of Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Canaccord Genuity Group upped their target price on shares of Repligen from $145.00 to $180.00 and gave the stock a “hold” rating in a research report on Monday, October 19th. Finally, UBS Group restated a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.57.

Read Our Latest Stock Report on Repligen

Repligen Company Profile

(Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

Further Reading

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.